Indrayani Biotech Ltd
Incorporated in 1992, Indrayani Biotech
Ltd is in the business of Foods & Hospitality, Engineering and Healthcare[1]
- Market Cap ₹ 171 Cr.
- Current Price ₹ 37.5
- High / Low ₹ 99.7 / 35.0
- Stock P/E 21.9
- Book Value ₹ 16.4
- Dividend Yield 0.00 %
- ROCE 14.0 %
- ROE 11.8 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 33.4%
- Tax rate seems low
- Promoter holding has decreased over last 3 years: -17.0%
- Working capital days have increased from 119 days to 219 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Hotels & Restaurants Industry: Hotels
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|
0 | 39 | 58 | 50 | 21 | 61 | 163 | 165 | 146 | |
0 | 39 | 57 | 47 | 26 | 54 | 145 | 142 | 123 | |
Operating Profit | -0 | 1 | 1 | 3 | -5 | 7 | 17 | 24 | 23 |
OPM % | -105% | 2% | 1% | 6% | -24% | 11% | 11% | 14% | 16% |
0 | 0 | 0 | 0 | -4 | 0 | 4 | 1 | 1 | |
Interest | 0 | 0 | 0 | 1 | 2 | 2 | 6 | 10 | 11 |
Depreciation | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 4 | 6 |
Profit before tax | -0 | 0 | 0 | 1 | -11 | 4 | 12 | 11 | 8 |
Tax % | 0% | 150% | 300% | 0% | 0% | 0% | 3% | 5% | |
-0 | -0 | -0 | 1 | -11 | 4 | 12 | 10 | 8 | |
EPS in Rs | -0.14 | -0.16 | 2.22 | -3.28 | 1.30 | 2.55 | 1.40 | 1.72 | |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 100% |
TTM: | -18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 43% |
TTM: | -10% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 50% |
3 Years: | 13% |
1 Year: | -39% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 18% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 4 | 4 | 4 | 34 | 34 | 34 | 46 | 46 |
Reserves | -6 | -0 | -0 | 27 | -15 | -10 | 10 | 18 | 29 |
0 | 0 | 0 | 14 | 16 | 19 | 79 | 113 | 100 | |
1 | 6 | 9 | 7 | 5 | 8 | 32 | 58 | 77 | |
Total Liabilities | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 252 |
1 | 6 | 6 | 17 | 15 | 17 | 57 | 62 | 61 | |
CWIP | -0 | 0 | 0 | 14 | 14 | 13 | 14 | 20 | 24 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 4 | 7 | 21 | 11 | 22 | 85 | 151 | 167 | |
Total Assets | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 252 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|
1 | 2 | 6 | 0 | 4 | 16 | -30 | ||
-3 | -0 | -4 | -1 | -1 | -47 | -16 | ||
2 | -1 | -1 | -0 | -3 | 33 | 44 | ||
Net Cash Flow | 0 | 1 | 1 | -1 | 1 | 2 | -2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 0 | 26 | 26 | 52 | 84 | 84 | 67 | 87 |
Inventory Days | 365 | 57 | 25 | 14 | 44 | 159 | ||
Days Payable | 365 | 70 | 77 | 52 | 81 | 141 | ||
Cash Conversion Cycle | 0 | 26 | 26 | 38 | 32 | 46 | 30 | 106 |
Working Capital Days | -1,883 | -1 | -8 | 80 | 71 | 56 | 83 | 219 |
ROCE % | 28% | 12% | -13% | 16% | 23% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Newspaper publications of unaudited financial results for the quarter and half year ended 30th September 2024.
-
Announcement under Regulation 30 (LODR)-Raising of Funds
15 Nov - Board approved financial results and rights issue.
-
.Pursuant To Regulation 33 Of SEBI (LODR) Regulations 2015, The Board Meeting Held On Today I.E, 14-11-2024 Has Approved The Unaudited Standalone And Consolidated Results For The Quarter Ended 30-09-2024.
15 Nov - Board approved unaudited financial results and rights issue.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14-08-2024 Is Attached.
14 Nov - Approval of financial results and rights issue.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14-08-2024 Is Attached.
14 Nov - Approved financial results and rights issue proposal.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
IBL has multiple business units managed by an
independent team of field experts. It operates
in Food and Hospitality, Dairy, Healthcare & Pharma, Engineering, Biotech, Agriculture and Infrastructure